المؤلفون: Al Bakir, M., Huebner, A., Martinez-Ruiz, C., Grigoriadis, K., Watkins, T. B. K., Pich, O., Moore, D. A., Veeriah, S., Ward, S., Laycock, J., Johnson, D., Rowan, A., Razaq, M., Akther, M., Naceur-Lombardelli, C., Prymas, P., Toncheva, A., Hessey, S., Dietzen, M., Colliver, E., Frankell, A. M., Bunkum, A., Lim, E. L., Karasaki, T., Abbosh, C., Hiley, C. T., Hill, M. S., Cook, D. E., Wilson, G. A., Salgado, R., Nye, E., Stone, R. K., Fennell, D. A., Price, G., Kerr, K. M., Naidu, B., Middleton, G., Summers, Yvonne J, Lindsay, Colin R, Blackhall, Fiona H, Cave, J., Blyth, K. G., Nair, A., Ahmed, A., Taylor, M. N., Procter, A. J., Falzon, M., Lawrence, D., Navani, N., Thakrar, R. M., Janes, S. M., Papadatos-Pastos, D., Forster, M. D., Lee, S. M., Ahmad, T., Quezada, S. A., Peggs, K. S., Van Loo, P., Dive, Caroline, Hackshaw, A., Birkbak, N. J., Zaccaria, S., Jamal-Hanjani, M., McGranahan, N., Swanton, C., Lester, J. F., Bajaj, A., Nakas, A., Sodha-Ramdeen, A., Ang, K., Tufail, M., Chowdhry, M. F., Scotland, M., Boyles, R., Rathinam, S., Wilson, C., Marrone, D., Dulloo, S., Matharu, G., Shaw, J. A., Riley, J., Primrose, L., Boleti, E., Cheyne, H., Khalil, M., Richardson, S., Cruickshank, T., Benafif, S., Gilbert, K., Patel, A. J., Osman, A., Lacson, C., Langman, G., Shackleford, H., Djearaman, M., Kadiri, S., Leek, A., Hodgkinson, J. D., Totten, N., Montero, A., Smith, E., Fontaine, E., Granato, F., Doran, H., Novasio, J., Rammohan, K., Joseph, L., Bishop, P., Shah, R., Moss, S., Joshi, V., Crosbie, P., Gomes, F., Brown, K., Carter, M., Chaturvedi, A., Priest, L., Oliveira, P., Krebs, M. G., Clipson, A., Tugwood, J., Kerr, A., Rothwell, D. G., Kilgour, E., Aerts, H., Schwarz, R. F., Kaufmann, T. L., Rosenthal, R., Szallasi, Z., Kisistok, J., Sokac, M., Diossy, M., Demeulemeester, J., Stewart, A., Magness, A., Karamani, A., Chain, B., Campbell, B. B., Castignani, C., Bailey, C., Puttick, C., Weeden, C. E., Lee, C., Richard, C., Pearce, D. R., Karagianni, D., Biswas, D., Levi, D., Hoxha, E., Cadieux, E. L., Gronroos, E., Galvez-Cancino, F., Athanasopoulou, F., Gimeno-Valiente, F., Kassiotis, G., Stavrou, G., Mastrokalos, G., Zhai, H. R., Lowe, H. L., Matos, I., Goldman, J., Reading, J. L., Black, J. R. M., Herrero, J., Rane, J. K., Nicod, J., Lam, J. M., Hartley, J. A., Enfield, K. S. S., Selvaraju, K., Thol, K., Litchfield, K., Ng, K. W., Chen, K. Z., Dijkstra, K., Thakkar, K., Ensell, L., Shah, M., Vasquez, M., Litovchenko, M., Sunderland, M. W., Leung, M., Escudero, M., Angelova, M., Tanic, M., Sivakumar, M., Kanu, N., Chervova, O., Lucas, O., Al-Sawaf, O., Hobson, P., Pawlik, P., Bentham, R., Hynds, R. E., Vendramin, R., Saghafinia, S., Lopez, S., Gamble, S., Ung, S. K. A., Vanloo, S., Boeing, S., Beck, S., Bola, S. K., Denner, T., Marafioti, T., Mourikis, T. P., Spanswick, V., Barbe, V., Lu, W. T., Hill, W., Liu, W. K., Wu, Y., Naito, Y., Ramsden, Z., Veiga, C., Royle, G., Collins-Fekete, C. A., Fraioli, F., Ashford, P., Clark, T., Borg, E., Wilson, J., Patrini, D., Hoogenboom, E. M., Monk, F., Holding, J. W., Choudhary, J., Bhakhri, K., Scarci, M., Hayward, M., Panagiotopoulos, N., Gorman, P., Khiroya, R., Stephens, R. C. M., Wong, Y. N. S., Bandula, S., Sharp, A., Smith, S., Gower, N., Dhanda, H. K., Chan, K., Pilotti, C., Leslie, R., Grapa, A., Zhang, H. Y., AbdulJabbar, K., Pan, X. X., Yuan, Y. Y., Chuter, D., MacKenzie, M., Chee, S., Alzetani, A., Scarlett, L., Richards, J., Ingram, P., Austin, S., Lim, E., De Sousa, P., Jordan, S., Rice, A., Raubenheimer, H., Bhayani, H., Ambrose, L., Devaraj, A., Chavan, H., Begum, S., Buderi, S. I., Kaniu, D., Malima, M., Booth, S., Nicholson, A. G., Fernandes, N., Shah, P., Proli, C., Hewish, M., Danson, S., Shackcloth, M. J., Robinson, L., Russell, P., Dick, C., Le Quesne, J., Kirk, A., Asif, M., Bilancia, R., Kostoulas, N., Thomas, M.

المساهمون: Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London

العلاقة: https://dx.doi.org/10.1038/s41586-023-05729-xTest; Al Bakir M, Huebner A, Martinez-Ruiz C, Grigoriadis K, Watkins TBK, Pich O, et al. The evolution of non-small cell lung cancer metastases in TRACERx. Nature. 2023 2023 Apr. PubMed PMID: WOS:000991048500004.; http://hdl.handle.net/10541/626391Test; Nature

الإتاحة: https://doi.org/10.1038/s41586-023-05729-xTest
http://hdl.handle.net/10541/626391Test

المؤلفون: Frankell, A. M., Dietzen, M., Al Bakir, M., Lim, E. L., Karasaki, T., Ward, S., Veeriah, S., Colliver, E., Huebner, A., Bunkum, A., Hill, M. S., Grigoriadis, K., Moore, D. A., Black, J. R. M., Liu, W. K., Thol, K., Pich, O., Watkins, T. B. K., Naceur-Lombardelli, C., Cook, D. E., Salgado, R., Wilson, G. A., Bailey, C., Angelova, M., Bentham, R., Martínez-Ruiz, C., Abbosh, C., Nicholson, A. G., Le Quesne, J., Biswas, D., Rosenthal, R., Puttick, C., Hessey, S., Lee, C., Prymas, P., Toncheva, A., Smith, J., Xing, W., Nicod, J., Price, G., Kerr, K. M., Naidu, B., Middleton, G., Blyth, K. G., Fennell, D. A., Forster, M. D., Lee, S. M., Falzon, M., Hewish, M., Shackcloth, M. J., Lim, E., Benafif, S., Russell, P., Boleti, E., Krebs, Matthew G, Lester, J. F., Papadatos-Pastos, D., Ahmad, T., Thakrar, R. M., Lawrence, D., Navani, N., Janes, S. M., Dive, Caroline, Blackhall, Fiona H, Summers, Yvonne J, Cave, J., Marafioti, T., Herrero, J., Quezada, S. A., Peggs, K. S., Schwarz, R. F., Van Loo, P., Miedema, D. M., Birkbak, N. J., Hiley, C. T., Hackshaw, A., Zaccaria, S., Jamal-Hanjani, M., McGranahan, N., Swanton, C.

المساهمون: Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK

العلاقة: https://dx.doi.org/10.1038/s41586-023-05783-5Test; Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023 Apr;616(7957):525-33. PubMed PMID: 37046096. Pubmed Central PMCID: PMC10115649 for tumour monitoring (PCT/EP2022/077987). M.A.B. has consulted for Achilles Therapeutics. D.A.M. reports speaker fees from AstraZeneca, Eli Lilly and Takeda, consultancy fees from AstraZeneca, Thermo Fisher, Takeda, Amgen, Janssen, MIM Software, Bristol-Myers Squibb (BMS) and Eli Lilly and has received educational support from Takeda and Amgen. S.V. is a co-inventor on a patent to detect molecules in a sample (US patent 10578620). G.A.W. is employed by and has stock options in Achilles Therapeutics. R.S. reports non-financial support from Merck and BMS, research support from Merck, Puma Biotechnology and Roche, and personal fees from Roche, BMS and Exact Sciences for advisory boards. C.A. has received speaking honoraria or expenses from Novartis, Roche, AstraZeneca and BMS and reports employment at AstraZeneca. C.A. is an inventor on a European patent application relating to assay technology to detect tumour recurrence (PCT/GB2017/053289); the patent has been licensed to commercial entities and under their terms of employment, C.A. is due a revenue share of any revenue generated from such licence(s). C.A. declares a patent application (PCT/US2017/028013) for methods to detect lung cancer. C.A. is a named inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987). C.A. is a named inventor on a provisional patent protection related to a ctDNA detection algorithm. D.B. reports personal fees from NanoString and AstraZeneca. He has a patent (PCT/GB2020/050221) issued on methods for cancer prognostication. R.R. is an employee of and has stock options in Achilles Therapeutics and holds a European patent on targeting neoantigens (PCT/EP2016/059401) and in determining HLA LOH (PCT/GB2018/052004). D.A.F. reports grants from Aldeyra, Boehringer Ingelheim, Astex Therapeutics, Bayer, BMS, GSK, RS Oncology, Clovis, Eli Lilly, MSD, GSK, personal fees from Atara, BMS, Boehringer Ingelheim, Cambridge Clinical Laboratories, Targovax, Roche and RS Oncology. M.D.F. acknowledges grant support from CRUK, AstraZeneca, Boehringer Ingelheim, MSD and Merck; is an advisory board member for Transgene; and has consulted for Achilles, Amgen, AstraZeneca, Bayer, Boxer, BMS, Celgene, EQRx, Guardant Health, Immutep, Ixogen, Janssen, Merck, MSD, Nanobiotix, Novartis, Oxford VacMedix, Pharmamar, Pfizer, Roche, Takeda and UltraHuman. K.S.P. is a co-founder of Achilles Therapeutics. S.A.Q. is a co-founder, stockholder and Chief Scientific Officer of Achilles Therapeutics. E.L. has received funding from AstraZeneca, Boehringer Ingelheim, Medela, Johnson & Johnson/Ethicon, Covidien/Medtronic, Guardant Health, Takeda, Lilly Oncology, Boehringer Ingelheim and Bayer. E.L. has received consulting fees from Beigene, Roche and BMS, honoraria from Medela and is a founder My Cancer Companion, Healthcare Companion Ltd. N.N. reports honoraria for non-promotional educational talks, advisory boards or conference attendance from Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Fujifilm, Guardant Health, Intuitive, Janssen, Lilly, Merck Sharp & Dohme, Olympus, OncLive, PeerVoice, Pfizer and Takeda. S.M.J. has received fees for advisory board membership in the past 3 years from AstraZeneca, Bard1 Lifescience and Johnson & Johnson. He has received a grant income from Owlstone and GRAIL Inc. He has received assistance with travel to an academic meeting from Cheisi. C.D. has received research funding and educational research grants from AstraZeneca, Astex Pharmaceuticals, Bioven, Amgen, Carrick Therapeutics, Merck, Taiho Oncology, GSK, Bayer, Boehringer Ingelheim, Roche, BMS, Novartis, Celgene, Epigene Therapeutics, Angle PLC, Menarini, Clearbridge Biomedics, Thermo Fisher Scientific and Neomed Therapeutics. C.D. has also received honoraria for consultancy and/or advisory boards from Biocartis, Merck, AstraZeneca, GRAIL and Boehringer Ingelheim. J.C. reports funding from Amgen to attend a conference. A. Hackshaw has received fees for being a member of Independent Data Monitoring Committees for Roche-sponsored clinical trials, and academic projects co-ordinated by Roche. N.J.B. is a co-inventor on a patent to identify responders to cancer treatment (PCT/GB2018/051912), has a patent application (PCT/GB2020/050221) on methods for cancer prognostication and is a co-inventor on a patent for methods for predicting anticancer responses (US14/466,208). C.T.H. has received speaker fees from AstraZeneca. M.J.-H. has consulted for and is a member of the Achilles Therapeutics Scientific Advisory Board (SAB) and Steering Committee, has received speaker honoraria from Pfizer, Astex Pharmaceuticals, Oslo Cancer Cluster, and holds a patent (PCT/US2017/028013) relating to methods for lung cancer detection. This patent has been licensed to commercial entities and under terms of employment, M.J.-H. is due a share of any revenue generated from such licence(s). N.M. has received consultancy fees and has stock options in Achilles Therapeutics. N.M. holds European patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004) and predicting survival rates of patients with cancer (PCT/GB2020/050221). C.S. acknowledges grant support from AstraZeneca, Boehringer-Ingelheim, BMS, Pfizer, Roche-Ventana, Invitae (previously Archer Dx (collaboration in minimal residual disease sequencing technologies)) and Ono Pharmaceutical. C.S. is an AstraZeneca Advisory Board member and Chief Investigator for the AZ MeRmaiD 1 and 2 clinical trials and is also Co-Chief Investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s SAB. He receives consultant fees from Achilles Therapeutics (also a SAB member), Bicycle Therapeutics (also a SAB member), Genentech, Medicxi, Roche Innovation Centre–Shanghai, Metabomed (until July 2022), and the Sarah Cannon Research Institute. C.S. had stock options in Apogen Biotechnologies and GRAIL until June 2021, and currently has stock options in Epic Bioscience, Bicycle Therapeutics, and has stock options and is co-founder of Achilles Therapeutics. C.S. is an inventor on a European patent application relating to an assay technology to detect tumour recurrence (PCT/GB2017/053289), the patent has been licensed to commercial entities and under his terms of employment, C.S. is due a revenue share of any revenue generated from such licence(s). C.S. holds patents relating to targeting neoantigens (PCT/EP2016/059401), identifying patient responses to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), a US patent relating to detecting tumour mutations (PCT/US2017/28013), methods for lung cancer detection (US20190106751A1) and both a European and US patent related to identifying indel mutation targets (PCT/GB2018/051892) and is a co-inventor on a patent application to determine methods and systems for tumour monitoring (PCT/EP2022/077987). C.S. is a named inventor on a provisional patent related to a ctDNA detection algorithm. Epub 2023/04/13. eng.; http://hdl.handle.net/10541/626225Test; Nature

الإتاحة: https://doi.org/10.1038/s41586-023-05783-5Test
http://hdl.handle.net/10541/626225Test

المؤلفون: Clarke, C. S., Hunter, R. M., Gabrio, A., Brawley, C. D., Ingleby, F. C., Dearnaley, D. P., Matheson, D., Attard, G., Rush, H. L., Jones, R. J., Cross, W., Parker, C., Russell, J. M., Millman, R., Gillessen, Silke, Malik, Z., Lester, J. F., Wylie, J., Clarke, Noel W, Parmar, M. K. B., Sydes, M. R., James, N. D.

المساهمون: Research Department of Primary Care and Population Health, University College London, London

العلاقة: https://dx.doi.org/10.1371/journal.pone.0269192Test; Clarke CS, Hunter RM, Gabrio A, Brawley CD, Ingleby FC, Dearnaley DP, et al. Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. Roviello G, editor. Vol. 17, PLOS ONE. Public Library of Science (PLoS); 2022. p. e0269192.; http://hdl.handle.net/10541/625353Test; PLoS One

الإتاحة: https://doi.org/10.1371/journal.pone.0269192Test
http://hdl.handle.net/10541/625353Test

المؤلفون: Hussain, S. A., Lester, J. F., Jackson, R., Gornall, M., Qureshi, M., Elliott, Tony, Crabb, S. J., Huddart, R. A., Vasudev, N., Birtle, A. J., Worlding, J., James, N. D., Parikh, O., Vilarino-Varela, M., Alonzi, R., Linch, M. D., Riaz, I. B., Catto, J. W. F., Powles, T., Jones, R. J.

المساهمون: Department of Oncology and Metabolism, Academic Unit of Oncology, University of Sheffield, Sheffield, UK.

العلاقة: https://dx.doi.org/10.1016/s1470-2045Test(22)00158-9; Hussain SA, Lester JF, Jackson R, Gornall M, Qureshi M, Elliott A, et al. Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. Vol. 23, The Lancet Oncology. Elsevier BV; 2022. p. 650–8.; http://hdl.handle.net/10541/625261Test; Lancet Oncology

الإتاحة: https://doi.org/10.1016/s1470-2045Test(22)00158-9
http://hdl.handle.net/10541/625261Test

المؤلفون: Hoskin, P. J., Hopkins, K., Misra, Vivek, Holt, T., McMenemin, R., McKinna, F., Madhavan, K., Bates, A., O'Rourke, N., Lester, J. F., Sevitt, T., Roos, D., Brown, G., Thomas, S. S., Forsyth, S., Reczko, K., Hackshaw, A., O'Hara, Catherine, Lopes, A.

المساهمون: Mount Vernon Cancer Centre Northwood and University of Manchester, United Kingdom

العلاقة: https://dx.doi.org/10.1016Test/j.radonc.2022.05.017; Hoskin PJ, Hopkins K, Misra V, Holt T, McMenemin R, McKinna F, et al. Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trial. Vol. 173, Radiotherapy and Oncology. Elsevier BV; 2022. p. 77–83.; http://hdl.handle.net/10541/625332Test; Radiotherapy and Oncology

الإتاحة: https://doi.org/10.1016Test/j.radonc.2022.05.017
http://hdl.handle.net/10541/625332Test

المؤلفون: Bayman, N., Ardron, D., Ashcroft, L., Baldwin, D. R., Booton, R., Darlison, L., Edwards, J. G., Lang-Lazdunski, L., Lester, J. F., Peake, M., Rintoul, R. C., Snee, M, Taylor, P., Lunt, C., Faivre-Finn, Corinne

المصدر: Bayman , N , Ardron , D , Ashcroft , L , Baldwin , D R , Booton , R , Darlison , L , Edwards , J G , Lang-Lazdunski , L , Lester , J F , Peake , M , Rintoul , R C , Snee , M , Taylor , P , Lunt , C & Faivre-Finn , C 2016 , ' Protocol for PIT: A phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention ' , BMJ Open , vol. 6 , no. 1 ....

مصطلحات موضوعية: ResearchInstitutes_Networks_Beacons/mcrc, Manchester Cancer Research Centre

الإتاحة: https://doi.org/10.1136/bmjopen-2015-010589Test
https://research.manchester.ac.uk/en/publications/0e2f5726-79a5-4810-881a-42ac8ab7a894Test

المؤلفون: Fennell, D. A., Ewings, S., Ottensmeier, C., Califano, Raffaele, Hanna, G. G., Hill, K., Danson, S., Steele, N., Nye, M., Johnson, L., Lord, J., Middleton, C., Szlosarek, P., Chan, S., Gaba, A., Darlison, L., Wells-Jordan, P., Richards, C., Poile, C., Lester, J. F., Griffiths, G., Investigators, C. T.

المساهمون: Mesothelioma Research Programme, Leicester Cancer Research Centre, University of Leicester, Leicester, UK, University Hospitals of Leicester NHS Trust, Leicester

العلاقة: Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial Vol. 22, The Lancet Oncology. Elsevier BV; 2021. p. 1530–40.; http://hdl.handle.net/10541/624968Test; Lancet Oncology

الإتاحة: https://doi.org/10.1016/s1470-2045Test(21)00471-x
http://hdl.handle.net/10541/624968Test

المؤلفون: Hudson, E, Powell, J, Mukherjee, S, Crosby, T D L, Brewster, A E, Maughan, T S, Bailey, H, Lester, J F

المصدر: British Journal of Cancer ; volume 96, issue 5, page 708-711 ; ISSN 0007-0920 1532-1827

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1038/sj.bjc.6603611Test
http://www.nature.com/articles/6603611.pdfTest
http://www.nature.com/articles/6603611Test

المؤلفون: Lawless, CA, Landau, DB, Faivre-Finn, Corinne, Boyd, K, Lester, J. F., Fenwick, J, Maguire, J, McCartney, E, Paul, J, Parsons, E, Peek, A, Haswell, T, Hatton, MQ

المصدر: Lawless , CA , Landau , DB , Faivre-Finn , C , Boyd , K , Lester , J F , Fenwick , J , Maguire , J , McCartney , E , Paul , J , Parsons , E , Peek , A , Haswell , T & Hatton , MQ 2017 , ' ADSCaN: A randomised phase II study of accelerated, dose escalated, sequential chemo-radiotherapy in non-small cell lung cancer (NSCLC) ' , pp. S80(171) . < http://www.lungcancerjournal.info/article/S0169-5002Test(16)30205-7/abstract >

مصطلحات موضوعية: ResearchInstitutes_Networks_Beacons/mcrc, Manchester Cancer Research Centre

الإتاحة: https://research.manchester.ac.uk/en/publications/e7e03ddf-07ed-4be4-8242-8af8fc06fbf5Test
http://www.lungcancerjournal.info/article/S0169-5002Test(16)30205-7/abstract

المؤلفون: Sanganalmath, P, Lester, J E, Bradshaw, A G, Das, T, Esler, C, Roy, A E F, Toy, Elizabeth, Lester, J F, Button, M, Wilson, P, Comins, C, Atherton, P, Pickles, R, Foweraker, K, Walker, G A, Keni, M, Hatton, M Q

مصطلحات موضوعية: Wessex Classification Subject Headings::Oncology. Pathology

العلاقة: http://linkinghub.elsevier.com/retrieve/pii/S0936-6555Test(17)30541-1; Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years' Experience From Nine UK Centres. 2018 30(3) 144-150 Clin Oncol (R Coll Radiol); http://hdl.handle.net/11287/620609Test; Clinical oncology (Royal College of Radiologists (Great Britain))

الإتاحة: https://doi.org/10.1016Test/j.clon.2017.12.019
http://hdl.handle.net/11287/620609Test